- Conditions
- Asthma
- Interventions
- MCT, Clazakizumab, Broncho-Vaxom, Imatinib Mesylate, Cavosonstat, Placebo
- Drug · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 950 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 29
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Placebo, Armodafinil
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphangioleiomyomatosis (LAM), Lymphangioleiomyomatosis
- Interventions
- Imatimib Mesylate, Placebo
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 64 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- New York, New York • Charleston, South Carolina
- Conditions
- COVID-19
- Interventions
- Imatinib, Placebo oral tablet
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Gastrointestinal Stromal Tumor
- Interventions
- imatinib mesylate, placebo, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 732 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Imatinib mesylate, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Newark, New Jersey • New York, New York
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- Regorafenib (Stivarga, BAY73-4506), Placebo, Best supportive care
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Evanston, Illinois • Skokie, Illinois + 6 more
- Conditions
- Lymphangioleiomyomatosis
- Interventions
- Imatinib Mesylate 400Mg Capsule, Placebo - Capsule
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- New York, New York • Charleston, South Carolina
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- imatinib mesylate, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
- Conditions
- Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1, Type 1 Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus 1, IDDM
- Interventions
- Imatinib Mesylate, Placebo (For imatinib mesylate)
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 8
- States / cities
- San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 5 more